NCT01804166 · ADVERSE EVENTS

Adverse events

A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL) · Source last updated 2025-02-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame: Approximately up to 8 years
Other-event reporting threshold: 0%

Participants affected / participants at risk, as reported
Safety group	Serious events	Other events	Deaths
IBD Patients With HSTCL Subjects with Inflammatory Bowel Disease with a diagnosis of Hepatosplenic T-cell lymphoma	0 / 1	0 / 1	0 / 1

Group identifiers: EG000: IBD Patients With HSTCL

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Other reported adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Complete source fields

event Groups

deaths Num Affected
0
deaths Num At Risk
1
description
Subjects with Inflammatory Bowel Disease with a diagnosis of Hepatosplenic T-cell lymphoma
id
EG000
other Num Affected
0
other Num At Risk
1
serious Num Affected
0
serious Num At Risk
1
title
IBD Patients With HSTCL

frequency Threshold

time Frame

Approximately up to 8 years

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice